Literature DB >> 2747308

Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.

H Ehrsson1, S Eksborg, A Osterborg, H Mellstedt, A Lindfors.   

Abstract

The pharmacokinetics of melphalan have been studied after oral doses of 5, 10 and 20 mg, and 10 mg i.v. Seven patients with multiple myeloma received the drug on 4 consecutive days and the concentration of melphalan was determined by liquid chromatography. Melphalan was rapidly absorbed after p.o. administration. Absorption lag-time was less than 1 h. The median time for attaining the peak concentration was 1.12 h (97% confidence interval: 0.68-1.55), 1.21 h (0.85-1.43) and 1.08 h (0.84-1.29) after doses of 5, 10 and 20 mg. The bioavailability showed large interindividual variations, and was not significantly affected by the dose given. There was a significant decrease in bioavailability during the treatment course (P less than 0.05). Absorption of melphalan obeys first-order kinetics in the dose interval studied. The results indicate that it might be of benefit to administrate oral melphalan for fewer days than the usually used 4 day regimen, in an attempt to achieve a higher bioavailability.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2747308     DOI: 10.1007/bf02985238

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  13 in total

1.  Quantitative determination of melphalan in plasma by liquid chromatography after derivatization with N-acetylcysteine.

Authors:  H Ehrsson; S Eksborg; A Lindfors
Journal:  J Chromatogr       Date:  1986-07-11

2.  The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.

Authors:  K W Woodhouse; P Hamilton; A Lennard; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  L-phenylalanine mustard (L-PAM): the first 25 years.

Authors:  R L Furner; R K Brown
Journal:  Cancer Treat Rep       Date:  1980 Apr-May

4.  Degradation of melphalan in aqueous solutions--influence of human albumin binding.

Authors:  H Ehrsson; U Lönroth
Journal:  J Pharm Sci       Date:  1982-07       Impact factor: 3.534

5.  High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.

Authors:  J Ninane; R Baurain; A de Selys; A Trouet; G Cornu
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.

Authors:  A G Bosanquet; E D Gilby
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.

Authors:  A G Bosanquet; E D Gilby
Journal:  Eur J Cancer Clin Oncol       Date:  1982-04

8.  The effect of food on oral melphalan absorption.

Authors:  P A Reece; D Kotasek; R G Morris; B M Dale; R E Sage
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Studies on the mechanism of gastrointestinal absorption of melphalan and chlorambucil.

Authors:  C G Adair; J C McElnay
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.

Authors:  I A Taha; R A Ahmad; H Gray; C I Roberts; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

View more
  6 in total

1.  A case of melphalan sustained accumulation in an 80-year old patient.

Authors:  Pierre-Alain Jolivot; Vianney Poinsignon; Angelo Paci; Bertrand Guidet; Claire Pichereau; Christine Fernandez; Patrick Hindlet
Journal:  Int J Clin Pharm       Date:  2015-09-22

2.  The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity.

Authors:  Fumiaki Kitazawa; Yoko Kado; Kumi Ueda; Takatoshi Kokufu; Shin-Ichi Fuchida; Akira Okano; Mayumi Hatsuse; Satoshi Murakami; Yuko Nakayama; Kohji Takara; Chihiro Shimazaki
Journal:  Mol Clin Oncol       Date:  2015-11-20

Review 3.  Current drug therapy for multiple myeloma.

Authors:  Y W Huang; A Hamilton; O J Arnuk; P Chaftari; R Chemaly
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

4.  Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).

Authors:  W Pönisch; P S Mitrou; K Merkle; M Herold; M Assmann; G Wilhelm; K Dachselt; P Richter; V Schirmer; A Schulze; R Subert; B Harksel; N Grobe; E Stelzer; M Schulze; A Bittrich; M Freund; R Pasold; Th Friedrich; W Helbig; D Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-10       Impact factor: 4.553

5.  Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro.

Authors:  H Ehrsson; R Lewensohn; I Wallin; M Hellström; G Merlini; B Johansson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.

Authors:  H F Rauschecker; H Foth; H C Michaelis; F Horst; W Gatzemeier; C Willenbrock; E Voth; G F Kahl
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.